Rittenhouse Ventures

Founder and Managing Partner Saul Richter leads the investment team alongside General Partners David Nevas and Sushma Rajagopalan. The six-person team operates from Wayne, Pennsylvania, and sources deals collectively, with each partner drawing on domain expertise in B2B technology and healthcare services.

The firm practices a capital-efficient staging model — typically writing smaller initial checks and following on as portfolio companies hit growth milestones. This method is designed to limit founder dilution and extend operating runway, distinguishing Rittenhouse from peers that favor larger upfront rounds.

While the firm is Philadelphia-based and concentrates sourcing in the Mid-Atlantic and Northeast, its portfolio spans the U.S. Active investments are located in New Jersey, New York, Massachusetts, and Texas, reflecting a willingness to back companies beyond its immediate geography when the sector fit is strong.

Rittenhouse invests across early-stage, expansion, and late-stage rounds, with a lean toward companies that have already demonstrated product-market fit in B2B technology or healthcare. The firm's staging philosophy means it often leads or participates in rounds sized to fund a specific growth milestone rather than a maximum raise.

Rittenhouse has not published a formal exclusion list, but the portfolio contains no consumer-facing, hardware, or deep-tech bets. The team's stated expertise sits in enterprise software, vertical SaaS, digital media monetization, and healthcare IT — indicating an implicit focus on B2B recurring-revenue models.

There is no public evidence of a parallel philanthropic foundation or donor-advised fund operated by the firm or its principals. Rittenhouse appears to be a pure play venture manager without a separate impact or charitable vehicle.

The firm's team page and investment announcements reference strategic and regional investor partnerships, but Rittenhouse does not describe a formal co-investment club or syndicate model. Co-investment opportunities appear to be evaluated on a deal-by-deal basis alongside the firm's own fund commitments.